Ankyra Therapeutics website screenshot

Ankyra Therapeutics

Ankyra Therapeutics is a clinical-stage biotechnology company based in Cambridge, Massachusetts, developing "anchored" immunotherapies for cancer and immune-mediated diseases. Its proprietary platform tethers immune-modulating drugs to aluminum hydroxide so that treatment concentrates locally at the disease site, broadening the therapeutic window while reducing systemic toxicity and dosing frequency. The lead candidate, ANK-101, is an anchored IL-12 therapy in clinical evaluation for patients with advanced solid tumors. Ankyra is backed by investors including Google Ventures (GV), Mithril, Polaris Partners, Sands Capital, and Fidelity. The company publishes no public developer API, SDK, or technical platform; this profile exists in the API Evangelist network for discovery and enrichment.

Ankyra Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Immunotherapy, and Oncology.

Ankyra Therapeutics’ developer surface includes engineering blog and 6 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyLife SciencesBiotechnologyImmunotherapyOncologyCancerClinical StagePharmaceuticals

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 8.1/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/ankyra-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Ankyra Therapeutics Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 5

The organization behind the API

Website
Website
 Blog
Blog
 Careers
Careers
 LinkedIn
LinkedIn
 Twitter
Twitter

Source (apis.yml)

apis.yml Raw ↑ 
aid: ankyra-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/ankyra-therapeutics.png
name: Ankyra Therapeutics
description: Ankyra Therapeutics is a clinical-stage biotechnology company based in Cambridge, Massachusetts, developing "anchored"
  immunotherapies for cancer and immune-mediated diseases. Its proprietary platform tethers immune-modulating drugs to aluminum
  hydroxide so that treatment concentrates locally at the disease site, broadening the therapeutic window while reducing systemic
  toxicity and dosing frequency. The lead candidate, ANK-101, is an anchored IL-12 therapy in clinical evaluation for patients
  with advanced solid tumors. Ankyra is backed by investors including Google Ventures (GV), Mithril, Polaris Partners, Sands
  Capital, and Fidelity. The company publishes no public developer API, SDK, or technical platform; this profile exists in
  the API Evangelist network for discovery and enrichment.
url: https://raw.githubusercontent.com/api-evangelist/ankyra-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Life Sciences
- Biotechnology
- Immunotherapy
- Oncology
- Cancer
- Clinical Stage
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/ankyra-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/ankyra-therapeutics-llms.txt
- type: Website
  url: https://ankyratx.com
- type: Blog
  name: News
  url: https://ankyratx.com/news/
- type: Careers
  url: https://ankyratx.com/our-team/join-our-team/
- type: LinkedIn
  url: https://www.linkedin.com/company/ankyratx
- type: Twitter
  url: https://twitter.com/ankyratx
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence